Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
11.38
-0.08 (-0.70%)
Streaming Delayed Price
Updated: 11:36 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evolus Inc
< Previous
1
2
3
Next >
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
January 17, 2024
Via
Investor Brand Network
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From
Evolus
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From
Evolus
Via
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From
Evolus
Via
Business Wire
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From
Evolus
Via
Business Wire
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Evolus
Via
Business Wire
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
November 07, 2023
From
Evolus
Via
Business Wire
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
November 06, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in November Investor Conferences
November 01, 2023
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2023 Results
October 25, 2023
From
Evolus
Via
Business Wire
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
October 25, 2023
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Evolus
Via
Business Wire
Evolus to Participate in September Conferences
August 29, 2023
From
Evolus
Via
Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
August 23, 2023
From
Evolus
Via
Business Wire
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
August 21, 2023
From
Evolus
Via
Business Wire
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
August 08, 2023
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Via
Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
August 08, 2023
From
Evolus
Via
Business Wire
Evolus Reports Second Quarter 2023 Results and Provides Business Update
August 02, 2023
From
Evolus
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.